Princeton, NJNCT07278479Now EnrollingIRB Ready

Large Cell Neuroendocrine Carcinoma Clinical Trial in Princeton, NJ

Access cutting-edge large cell neuroendocrine carcinoma treatment through this clinical trial at a research site in Princeton. Study-provided care at no cost to qualified participants.

Sponsored by Molecular Partners AG

Quick Self-Assessment

See if you qualify for this Princeton location

Preparing your pre-screening questions…

Expert Care in Princeton

Access large cell neuroendocrine carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related large cell neuroendocrine carcinoma treatment provided free

Apply for This Princeton Location

Check if you qualify for this large cell neuroendocrine carcinoma clinical trial in Princeton, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Princeton

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Princeton site if eligible
  4. 4Begin participation

About This Large Cell Neuroendocrine Carcinoma Study in Princeton

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.

Sponsor: Molecular Partners AG

Who Can Participate

Inclusion Criteria

Age ≥ 18 years old
Histologically or cytologically confirmed: I. advanced extensive or limited SCLC or LC NECs of the lung
SCLC (extensive stage, or limited stage) patients with progression or recurrence following at least two prior line of systemic platinum based therapy and immunotherapy or are not suitable or tolerating the standard of care treatment as second line of systemic therapy, or
LC NEC of the lung patients with progression or recurrence following at least one prior line of systemic therapy, or II. epNECs with progression or recurrence following at least one prior line of systemic therapy:
Gastroenteropancreatic NECs (GEPNEC), or
Cervical NECs, or
Bladder NECs, or
other epNECs with previously confirmed DLL3 expression by IHC.
Patients with prior DLL3-targeted therapy are allowed.
For epNECs in Part 1 and Part 2 and SCLC or LC NECs of the lung in Part 2: DLL3-positivity by \[203Pb\]Pb-DOTAM-MAM279 SPECT/CT
Radiographically documented disease progression or recurrence during or after the last line of systemic treatment therapy
At least one measurable disease per RECIST v1.1.
Adequate bone marrow reserve and organ function as demonstrated by complete blood count, and biochemistry in blood and urine at Screening
Adequate blood counts: Hemoglobin ≥9 g/dL; Absolute neutrophil count (ANC) ≥1.5 × 10\^9/L; Platelets ≥100 × 10\^9/L; White blood cells (WBC) ≥2.5 x 10\^9/L;
Adequate hepatic function
Adequate renal function: Calculated glomerular filtration rate (GFR) \>60mL/min (using Cockroft-Gault formula).
Patients with known central nervous system (CNS) metastasis will be eligible if they are clinically stable. Key

Exclusion Criteria

Uncontrolled intercurrent illness
Patients who have not had resolution of all clinically significant toxic effects of prior systemic cancer therapy, surgery, or radiotherapy to Grade ≤1 (except for grade ≤2 alopecia, or stable grade 2 sensory neuropathy, according to the last CTCAE version).
Active clinically significant cardiac disease
Evidence of interstitial lung disease or active, non-infectious pneumonitis.
History of other malignancy within the past 2 years with exceptions. Other protocol-defined inclusion/exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Princeton?

Yes, this clinical trial (NCT07278479) has an active research site in Princeton, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Large Cell Neuroendocrine Carcinoma Treatment Options in Princeton, NJ

If you're searching for large cell neuroendocrine carcinoma treatment options in Princeton, NJ, this clinical trial (NCT07278479) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Princeton research site is actively enrolling participants for this clinical trial. You'll receive care from experienced large cell neuroendocrine carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all large cell neuroendocrine carcinoma clinical trials near you to find additional studies recruiting in your area.

More Neuroendocrine Tumors Trials in Princeton, NJ

See all neuroendocrine tumors clinical trials recruiting in Princeton — not just this study.

Browse Neuroendocrine Tumors Trials in Princeton →

Browse More Trials by Condition

Neuroendocrine Tumors TrialsAll Conditions →

Ready to Join in Princeton?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Princeton, NJ